These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 19765255)

  • 1. Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroidism?
    Kakuta T; Tanaka R; Kanai G; Sawaya A; Hirukawa T; Sato A; Saito A
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S20-7. PubMed ID: 19765255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
    Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
    J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
    Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D
    Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
    Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
    Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
    Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
    Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
    N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy.
    Lomonte C; Antonelli M; Losurdo N; Marchio G; Giammaria B; Basile C
    Nephrol Dial Transplant; 2007 Jul; 22(7):2056-62. PubMed ID: 17449495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreases in parathyroid gland volume after cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism.
    Ichii M; Ishimura E; Okuno S; Chou H; Kato Y; Tsuboniwa N; Nagasue K; Maekawa K; Yamakawa T; Inaba M; Nishizawa Y
    Nephron Clin Pract; 2010; 115(3):c195-202. PubMed ID: 20413997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
    Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
    Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
    Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA;
    Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride.
    Sumida K; Nakamura M; Ubara Y; Marui Y; Tanaka K; Takaichi K; Tomikawa S; Inoshita N; Ohashi K
    J Clin Pathol; 2011 Sep; 64(9):756-60. PubMed ID: 21565858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism.
    Yamamoto M; Ogata H; Mizobuchi M; Yoshida N; Kumata-Maeta C; Koiwa F; Shishido K; Kinugasa E
    Clin Exp Nephrol; 2012 Apr; 16(2):292-9. PubMed ID: 22011886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
    Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
    Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis.
    Montenegro J; Cornago I; Gallardo I; García-Ledesma P; Hernando A; Martinez I; Muñoz RI; Romero MA
    Nephrology (Carlton); 2012 Jan; 17(1):26-31. PubMed ID: 22022934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study.
    Komaba H; Fukagawa M;
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S44-9. PubMed ID: 19032527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cinacalcet upregulates calcium-sensing receptors of parathyroid glands in hemodialysis patients.
    Sumida K; Nakamura M; Ubara Y; Marui Y; Tanaka K; Takaichi K; Tomikawa S; Inoshita N; Ohashi K
    Am J Nephrol; 2013; 37(5):405-12. PubMed ID: 23594726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study.
    Zitt E; Rix M; Ureña Torres P; Fouque D; Jacobson SH; Pétavy F; Dehmel B; Ryba M
    Nephrol Dial Transplant; 2011 Jun; 26(6):1956-61. PubMed ID: 20947534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal.
    Paschoalin RP; Torregrosa JV; Barros X; Durán CE; Campistol JM
    Transplant Proc; 2012 Oct; 44(8):2376-8. PubMed ID: 23026597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.